Active Biotech to conduct guaranteed preferential rights issue for approximately SEK 240 M

Active Biotech to conduct guaranteed preferential rights issue for approximately SEK 240 M. The issue entitles current shareholders preferential rights to subscribe for one new share for each twelve shares held at an issue price of SEK 60 per share.

MGA Holding AB, with 28.6 percent of the capital, and Nordstjernan AB, with 10.5 percent of the capital, have committed to subscribe for the full amount of shares corresponding to their preferential rights. In addition, MGA Holding AB and Nordstjernan AB jointly guarantee to fully subscribe for any additional shares for which current shareholders choose not to subscribe, in return for a customary guarantee commission. Furthermore, MGA Holding AB and Nordstjernan AB have committed to, if required, through conversion of convertibles and subsequent subscription of shares with preferential rights, secure that the company in this rights issue is provided with a total of approximately SEK 240 M.

The purpose of the issue is to enable continued development of the company’s extensive clinical portfolio. Several important results have been reported in 2006 and new studies have commenced, which means that projects will enter larger and more capital-intensive clinical development phases in 2007. The preclinical activities will also be expanded in the next year. This requires the strengthening of the company’s financial position.

Source: Press-release Active Biotech, 18.12.2006.

Read more at the Active Biotech homepage.